Abstract
Hypersensitivity brought on by Aspergillus causes a lung illness known as allergic bronchopulmonary aspergillosis (ABPA). ABPA is a common fungal disease that affects individuals with uncontrolled asthma, cystic fibrosis, and immunocompromised patients. Aspergillus mould species are highly prevalent in the environment, especially in organic waste. There are more than a hundred different species of Aspergillus throughout the world, but the most common offenders are Aspergillus fumigatus, Aspergillus niger, Aspergillus flavus, and Aspergillus clavatus. Several Aspergillus species, most notably Aspergillus fumigatus, are responsible for human diseases. Depending on the amount and virulence of inhaled Aspergillus and the host’s genetic vulnerability and immunity, Aspergillus can produce allergic or allergic (Aspergillus-mediated allergies and asthma, hypersensitivity pneumonia, and ABPA pulmonary disorders. Because of its unique appearance, particularly when there is no medical history of asthma, it may be challenging to diagnose in some circumstances. Although side effects from treating ABPA are regularly described, cumulative medication toxicity caused by several compounds is uncommon. It’s essential to make a wise decision among the several compounds that are available and efficient against ABPA. We document a case of ABPA in a female patient who had no prior history of asthma. She had complained about having trouble breathing. The presence of specific IgE antibodies against Aspergillus fumigatus & an elevated eosinophil count were used to make the diagnosis of ABPA.